Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sharp Therapeutics Corp. ( (TSE:SHRX) ) has shared an announcement.
Sharp Therapeutics Corp. has nominated a small molecule compound for clinical development in Gaucher’s disease, marking a significant milestone as the company transitions to a clinical stage. The nominated compound, part of the SEL-148,721 series, aims to restore enzymatic activity in patients with Gaucher’s disease, offering a more convenient and efficient alternative to current enzyme replacement therapies. This development could potentially expand treatment options to include CNS manifestations of the disease, a market not effectively addressed by existing therapies.
More about Sharp Therapeutics Corp.
Sharp Therapeutics Corp. is a pre-clinical stage biotechnology company focused on developing small-molecule therapeutics for hereditary disorders. Utilizing its Disco™ discovery platform, Sharp aims to create orally-available compounds that restore activity in mutated proteins, offering potential treatments for genetic diseases with conventional pill-based medicines.
Average Trading Volume: 2,893
See more insights into SHRX stock on TipRanks’ Stock Analysis page.